Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ArtivionAORT +0.37%80 3-Year EBITDA Growth Rate is 28.20% as of Jun. 2026, which is 442% above its 10-year median of 5.20. GuruFocus rates AORT with a GF Score™ of 80/100 and a GF Value™ of $28.91 (Fairly Valued). The stock has 3 warning signs investors should review. Among 690 Medical Devices & Instruments companies, Artivion ranks better than 75.51% on this metric.
During the past 12 months, Artivion's average EBITDA Per Share Growth Rate was 11.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 28.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 20.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 6.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Artivion was 73.40% per year. The lowest was -15.50% per year. And the median was 5.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Artivion 3-Year EBITDA Growth Rate Related Terms
AORT vs IRMD, ATEC, TNDM: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Artivion's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artivion 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Artivion's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Artivion's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 28.20% mean?
Artivion (AORT) has a 3-Year EBITDA Growth Rate of 28.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Artivion and its competitors. This is 442% above median its historical median of 5.20. According to the industry distribution chart, Artivion ranks #169 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 24.5%.
Is Artivion's 3-Year EBITDA Growth Rate too high?
Artivion's current 3-Year EBITDA Growth Rate of 28.20% is 442% above median its 10-year median of 5.20. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. Artivion's value of 28.20% is 248.1% above this industry median. Based on the distribution chart, Artivion ranks #169 out of 690 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Artivion has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Artivion's 3-Year EBITDA Growth Rate compare to IRMD and ATEC?
According to the Medical Devices & Instruments industry distribution chart, Artivion ranks #169 out of 690 companies for 3-Year EBITDA Growth Rate. This places Artivion in the top 25% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.10. Artivion's value of 28.20% is 248.1% above this benchmark. While the company's 10-year median is 5.20 vs. the industry median of 8.10, Artivion has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Artivion's current 3-Year EBITDA Growth Rate of 28.20% is 248.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Artivion and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Artivion's current 3-Year EBITDA Growth Rate is 28.20%, which is 442% above median its own 10-year median of 5.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artivion stock overvalued right now?
Based on GuruFocus' analysis, Artivion (AORT) is currently considered Fairly Valued. The stock's GF Value™ is $28.91, compared to a current price of $26.77 — trading 7.4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 28.20%, which is 442% above median its 10-year median of 5.20 and 248.1% above the Medical Devices & Instruments industry median of 8.10. Artivion's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Artivion (AORT), the current 3-Year EBITDA Growth Rate is 28.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Artivion (AORT) Overvalued in 2026?
Based on GuruFocus' analysis, Artivion stock appears to be undervalued.
The current stock price of $26.77 is trading 7.4% below its estimated GF Value™ of $28.91.
GuruFocus considers Artivion to be Fairly Valued.
Key valuation signals for AORT:
3-Year EBITDA Growth Rate: 28.20% (442% above median its 10-year median of 5.20)
GF Value™: $28.91 vs. price of $26.77 (7.4% below fair value)
Industry Position: 248.1% above the Medical Devices & Instruments median (#169 of 690)
No single metric tells the full story. See the AORT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
80GF Score
Get the complete analysis for AORT
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AORT has been successfully added to your 
